Turning Over a New Leaf-Pharmacologic Therapy in Obstructive Sleep Apnea.

Jan Hedner, Ding Zou

Journal: Sleep medicine clinics 2022;17(3):453-469

PMID: 36150807

Full Text on Elsevier Science View on PubMed

Abstract

Despite extensive research, there is currently no approved drug for obstructive sleep apnea (OSA) treatment. OSA is a heterogeneous condition that involves multiple dominating pathophysiological traits. Drug development in this field needs to address both pathophysiological mechanisms and associated comorbid conditions in order to meet requirements for long-term therapy in OSA. Several drug candidates have been proposed and ongoing phase II trials that target various forms of sleep-disordered breathing have been initiated. The field is moving toward tailored therapeutic approaches in patients with OSA.

Address: Center for Sleep and Vigilance Disorders, Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy, University of Gothenburg, Medicinaregatan 8B, Box 421, Gothenburg SE-40530, Sweden.; Center for Sleep and Vigilance Disorders, Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy, University of Gothenburg, Medicinaregatan 8B, Box 421, Gothenburg SE-40530, Sweden. Electronic address: [email protected].

DOI: 10.1016/j.jsmc.2022.06.010

Link outs

Free resources

Medical:

https://medlineplus.gov/sleepapnea.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Continuous Positive Airway Pressure, Humans, Sleep Apnea Syndromes, Sleep Apnea, Obstructive